updated 5/10/2010 9:27:00 AM ET 2010-05-10T13:27:00

Cypress Bioscience Inc. said Monday its first-quarter loss narrowed on a sharp decline in research and development expenses and higher revenue.

The bulk of its revenue came from Savella, a drug for the pain disorder Fibromylagia. Forest Laboratories markets the drug.

Cypress Bioscience reported a net loss of $4.6 million, or 12 cents per share, compared with a loss of $9.2 million, or 24 cents per share, a year earlier.

Revenue rose to $8.1 million from $7.9 million.

Operating expenses fell 27 percent to $12.9 million, mainly on lower costs research and development costs.

Analysts polled by Thomson Reuters expected a smaller loss of 10 cents on $8.5 million in revenue.

Shares of Cypress Bioscience closed at $4.54 Friday.

Copyright 2010 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com